GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chong Kun Dang Pharmaceutical Corp (XKRX:185750) » Definitions » Shiller PE Ratio

Chong Kun Dang Pharmaceutical (XKRX:185750) Shiller PE Ratio : 19.45 (As of May. 26, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Chong Kun Dang Pharmaceutical Shiller PE Ratio?

As of today (2024-05-26), Chong Kun Dang Pharmaceutical's current share price is ₩106000.00. Chong Kun Dang Pharmaceutical's E10 for the quarter that ended in Mar. 2024 was ₩5,448.88. Chong Kun Dang Pharmaceutical's Shiller PE Ratio for today is 19.45.

The historical rank and industry rank for Chong Kun Dang Pharmaceutical's Shiller PE Ratio or its related term are showing as below:

XKRX:185750' s Shiller PE Ratio Range Over the Past 10 Years
Min: 18.21   Med: 20.24   Max: 23.42
Current: 19.45

During the past years, Chong Kun Dang Pharmaceutical's highest Shiller PE Ratio was 23.42. The lowest was 18.21. And the median was 20.24.

XKRX:185750's Shiller PE Ratio is ranked better than
66.73% of 535 companies
in the Drug Manufacturers industry
Industry Median: 24.25 vs XKRX:185750: 19.45

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Chong Kun Dang Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was ₩2,009.700. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₩5,448.88 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Chong Kun Dang Pharmaceutical Shiller PE Ratio Historical Data

The historical data trend for Chong Kun Dang Pharmaceutical's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chong Kun Dang Pharmaceutical Shiller PE Ratio Chart

Chong Kun Dang Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 24.49

Chong Kun Dang Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 24.49 20.22

Competitive Comparison of Chong Kun Dang Pharmaceutical's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Chong Kun Dang Pharmaceutical's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chong Kun Dang Pharmaceutical's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Chong Kun Dang Pharmaceutical's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Chong Kun Dang Pharmaceutical's Shiller PE Ratio falls into.



Chong Kun Dang Pharmaceutical Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Chong Kun Dang Pharmaceutical's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=106000.00/5448.88
=19.45

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Chong Kun Dang Pharmaceutical's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Chong Kun Dang Pharmaceutical's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2009.7/118.8477*118.8477
=2,009.700

Current CPI (Mar. 2024) = 118.8477.

Chong Kun Dang Pharmaceutical Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 864.188 99.353 1,033.756
201409 697.889 99.608 832.689
201412 275.034 99.098 329.847
201503 461.943 99.720 550.550
201506 -1,996.300 100.050 -2,371.371
201509 633.217 100.110 751.737
201512 389.453 100.220 461.840
201603 420.013 100.560 496.396
201606 552.199 100.790 651.132
201609 1,126.430 101.460 1,319.472
201612 994.954 101.560 1,164.317
201703 822.969 102.850 950.977
201706 808.045 102.610 935.916
201709 1,192.520 103.490 1,369.487
201712 1,048.970 102.990 1,210.483
201803 205.209 104.100 234.281
201806 919.337 104.130 1,049.276
201809 982.019 105.650 1,104.692
201812 1,116.040 104.350 1,271.095
201903 785.877 104.490 893.862
201906 916.726 104.880 1,038.814
201909 1,050.710 105.200 1,187.020
201912 1,342.100 105.120 1,517.366
202003 1,296.580 105.540 1,460.068
202006 2,003.280 104.870 2,270.289
202009 2,533.100 106.200 2,834.775
202012 1,136.480 105.765 1,277.053
202103 1,092.750 107.357 1,209.708
202106 1,743.220 107.579 1,925.826
202109 156.355 108.759 170.858
202112 274.225 109.676 297.156
202203 1,283.450 111.806 1,364.286
202206 1,710.660 114.083 1,782.109
202209 2,113.380 114.831 2,187.299
202212 894.966 115.200 923.303
202303 2,806.670 116.550 2,862.011
202306 3,355.240 117.140 3,404.157
202309 3,576.190 119.111 3,568.279
202312 6,958.290 118.848 6,958.290
202403 2,009.700 118.848 2,009.700

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Chong Kun Dang Pharmaceutical  (XKRX:185750) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Chong Kun Dang Pharmaceutical Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Chong Kun Dang Pharmaceutical's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Chong Kun Dang Pharmaceutical (XKRX:185750) Business Description

Traded in Other Exchanges
N/A
Address
368 Chungjungro-3Ga, Seodaemun-gu, Seoul, KOR, 120-756
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).

Chong Kun Dang Pharmaceutical (XKRX:185750) Headlines

No Headlines